Developer docs
API playgroundTry for free, no card

Search company profiles

Bioptimus

Full company profile

uuid00002xv

Namestring
Bioptimus
Legal namestring
Bioptimus
Websiteurl
bioptimus.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Bioptimus is a Paris-based AI startup founded in 2024 that builds multimodal foundation models for biology, targeting pharmaceutical R&D, translational research, and precision medicine. The company's product stack comprises three pillars: H-Optimus, a 1.1 billion-parameter Vision Transformer pathology foundation model (H-Optimus-0 open-source under Apache 2.0; H-Optimus-1 ranked #1 on PathBench and HEST benchmarks across 229 tasks); M-Optimus, the first foundation model that jointly learns from H&E pathology, bulk RNA-seq, spatial transcriptomics, and clinical data to predict the activity of 20,000 genes from routine slides; and STELA, a multi-institutional data engine with 10x Genomics and Broad Clinical Labs targeting up to 100,000 profiled patient specimens across the US, Europe, and Asia. Underlying architecture combines ViT-g/14 image encoders with multimodal pretraining, supporting applications including drug target discovery, biomarker identification, indication expansion, and clinical trial enrichment.

Short descriptiontext

Bioptimus builds multimodal foundation models for biology (H-Optimus, M-Optimus, STELA) used by 16 of the top 20 pharma companies and 1,000+ academic institutions for drug discovery, biomarker development, and clinical trial enrichment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
foundation models biology, computational pathology AI, multimodal biomedical models, drug discovery AI, spatial transcriptomics
Industry3 codes
PRIMARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers51321
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Foundation Models for Biology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Industry / commercial licensing
TypeLicensing Royalties
Description

Commercial use of H-Optimus-1, H-Optimus-0, M-Optimus, and STELA data atlas requires a separate licensing agreement (industry licenses). Deployed through Amazon SageMaker on AWS Marketplace for enterprise customers. Used by 16 of top 20 pharma companies.

bioptimus.com
2Academic / non-commercial access
TypeFreemium
Description

Universities and research institutions can request non-commercial research licenses for evaluation and experimental use. H-Optimus-0 is open-source under Apache 2.0; H-Optimus-1 and H0-mini are under CC-BY-NC-ND 4.0 for academic use.

bioptimus.com
3Strategic pharma collaborations & services
TypeProfessional Services
Description

Co-development and pilot deployments with pharmaceutical partners (top pharma already onboarded as pioneer partners for M-Optimus), including access to STELA data backbone for joint drug discovery, clinical trial enrichment, and biomarker development programs.

bioptimus.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Pricing details2 tiers
1Industry license for H-Optimus-1 / M-Optimus (quote-based)
ModelOtherBilling cadenceAnnual
Notes

Pricing not publicly disclosed; commercial use requires a separate licensing agreement obtained via direct contact. Available on AWS Marketplace via Amazon SageMaker.

bioptimus.com
2Academic non-commercial license
ModelFreemium
Notes

Free for academic / non-commercial research. H-Optimus-0 under Apache 2.0; H-Optimus-1 and H0-mini under CC-BY-NC-ND 4.0; M-Optimus available via request-access early-access program with top pharmaceutical companies already onboarded.

bioptimus.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1H-Optimus
Description

Bioptimus's pathology foundation model family (H-Optimus-0 and H-Optimus-1) for digital histopathology, providing state-of-the-art performance across pathology benchmarks.

bioptimus.com
+2 more records
Core offering1 text field

Bioptimus builds and licenses AI foundation models for biology. Its core products are H-Optimus (a state-of-the-art pathology foundation model trained on over 1 million H&E whole-slide images), M-Optimus (a multimodal world model that jointly learns from histology, RNA-seq, spatial transcriptomics, and clinical data), and STELA (a multi-institutional spatial biology atlas initiative). Models are licensed commercially to pharmaceutical and biotechnology customers (with academic/non-commercial access via Hugging Face and AWS Marketplace).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 12 values shown
  • H-Optimus-1 ranked #1 on PathBench with score 6.06 (vs Virchow 26.34, H-Optimus-0 6.86, UNI 27.10, mSTAR 7.65)
+11 more records
Product overview1 text field

Bioptimus offers a unified AI foundation model platform for biology structured around three integrated pillars: (1) H-Optimus, a single-modality pathology foundation model family (H-Optimus-0, H-Optimus-1, H0-mini) that serves as the histopathology backbone for biomarker discovery, patient stratification, and clinical decision support; (2) M-Optimus, the multimodal multi-scale 'world model of biology' that extends H-Optimus by jointly learning from H&E, bulk RNA-seq, spatial transcriptomics, and clinical data to predict gene expression and trial outcomes; and (3) STELA, a collaborative data generation engine that feeds M-Optimus with deeply profiled, clinically linked multimodal patient specimens. Together, these products form a vertically integrated stack in which H-Optimus provides the visual foundation, M-Optimus the reasoning and prediction layer, and STELA the proprietary data backbone, all designed to accelerate drug discovery, de-risk clinical trials, and advance precision medicine.

Product and service5 records
1H-Optimus-1
CategoryPathology foundation model
Description

A state-of-the-art 1.1 billion parameter Vision Transformer (ViT-g/14) foundation model for digital pathology, trained on over 1 million H&E whole-slide images from more than 800,000 patients across 4,000+ clinical centers and 50+ organs. Ranked #1 on PathBench across 229 tasks; available on AWS Marketplace and Hugging Face for academic use. Sold via enterprise licensing to pharmaceutical and biotech customers.

2H-Optimus-0
CategoryOpen-source pathology foundation model
Description

The original open-source 1.1 billion parameter pathology foundation model, trained on over 500,000 histology slides from 4,000+ clinical practices. Released under Apache 2.0 license, designed for broad academic and research use via Hugging Face.

3H0-mini
CategoryLightweight derivative pathology model
Description

A lightweight, computationally efficient pathology model distilled from H-Optimus-0 in collaboration with Owkin, delivering comparable performance to larger foundation models at significantly reduced inference cost. Released under CC-BY-NC-ND 4.0 license for non-commercial academic research on Hugging Face.

4M-Optimus
CategoryMultimodal foundation model for biology
Description

A multimodal, multi-scale foundation model that combines H&E pathology images, bulk RNA-seq, spatial transcriptomics, and clinical data into a unified embedding space. The first model built to understand biology across every scale, enabling digital twin simulations, drug target prediction, biomarker discovery, and trial design optimization. Request-access only via direct enterprise license.

5STELA (Spatial Tissue Embedding Learning Atlas)
CategorySpatial biology data atlas
Description

A multi-institutional collaborative data initiative, launched with 10x Genomics and Broad Clinical Labs, designed to generate the world's largest clinically linked multimodal spatial biology atlas profiling up to 100,000 patient tissue specimens across the US, Europe, and Asia. Serves as the proprietary data backbone for M-Optimus.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-25
Description

Co-launch partner of the STELA multinational spatial biology atlas initiative announced March 25, 2026. Provides the Xenium spatial transcriptomics platform used to profile up to 100,000 patient specimens across US, Europe and Asia. Bioptimus plans to expand from Xenium to Atera in 2027 as part of STELA. Michael Schnall-Levin (CTO and Founding Scientist of 10x Genomics) is a Bioptimus Strategic Advisor.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-25
Description

Co-launch partner of the STELA initiative alongside Bioptimus and 10x Genomics. Contributes high-throughput spatial data generation capabilities to profile up to 100,000 patient tissue specimens across three continents.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-03
Description

MIT partners with Bioptimus for the ARPA-H ADAPT Clinical Cancer Prediction Study (case study published November 3, 2025). MIT team led by Professor Regina Barzilay validated H-Optimus-1 as top-performing pathology foundation model for predicting Progression-Free Survival in metastatic breast, lung, and colon cancer. Regina Barzilay (MIT Jameel Clinic) also serves on Bioptimus's Scientific Advisory Board.

Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2025-06-11
Description

Bioptimus secured access to NVIDIA compute resources (via DGX Cloud Lepton) in June 2025 to accelerate training of its foundation models for biology, in collaboration with Sofinnova Partners.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-23
Description

Collaboration announced October 23, 2024 to accelerate AI innovation in scientific research and drug development for improved patient care; jointly hosted a December 2024 webinar on foundation models in pathology AI.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-02-20
Description

Founding-partner relationship — Bioptimus co-founders include ex-Owkin scientists (Jean-Philippe Vert was Chief R&D Officer; David Cahané was Chief Solutions Officer; Charlie Saillard worked at Owkin for 6 years; Philip Conti-Permanne was Director Corporate Development). Provides multimodal patient data, expertise, and a co-development collaboration for the CytoSyn diffusion model (released Nov 2025 on Hugging Face). Thomas Clozel (Owkin co-founder/CEO) serves as a Strategic Advisor.

Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2024-02-20
Description

Provides compute resources and cloud infrastructure. H-Optimus-1 is deployed on AWS Marketplace via Amazon SageMaker (launched May 2025) and M-Optimus / H-Optimus-1 are made available via Amazon SageMaker AI partnership.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Sarah Teichmann (Chair in Stem Cell Medicine, University of Cambridge; co-founder EnsoCell Therapeutics) serves as Chair of Bioptimus's Scientific Advisory Board.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Andrea Califano (President of CZI Biohub New York; Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia) sits on Bioptimus's Scientific Advisory Board.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Caroline Uhler (Director of the Eric & Wendy Schmidt Center at the Broad Institute; Professor of Engineering at MIT) is on Bioptimus's Scientific Advisory Board.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Jakob Kather (Professor for Clinical AI at TU Dresden; senior physician in medical oncology) is on Bioptimus's Scientific Advisory Board. The Kather Lab at TU Dresden is also a Bioptimus case-study customer using H-Optimus-1 for breast cancer recurrence risk prediction.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

John Connolly (CSO at PICI) sits on Bioptimus's Scientific Advisory Board.

13Berlin Institute for Medical Systems Biology / Max Delbrück Center (Nikolaus Rajewsky)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Nikolaus Rajewsky (Scientific and Founding Director, BIMSB at MDC) is on Bioptimus's Scientific Advisory Board.

bioptimus.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Fabrice André (President of ESMO; Director of Research at Gustave Roussy) is on Bioptimus's Scientific Advisory Board.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Insitro uses ML on multimodal biological data (imaging, genomics, functional assays) for drug discovery. It overlaps with Bioptimus on the ML-meets-biology thesis and pharma partnership model, but focuses on owned therapeutic pipelines rather than platform licensing.

TypeDirect peer
Description

Owkin is Bioptimus's founding partner and most direct competitor, building AI for patient stratification, drug discovery, and pathology. The two share scientific DNA (multiple Bioptimus co-founders came from Owkin) and overlapping multimodal patient data, but Owkin has deeper pharma deployment (e.g., Roche alliance) and a longer commercial track record.

TypeEmerging player
Description

Exscientia applies AI to small-molecule drug discovery, with a precision medicine focus and pharma partnerships. It is thematically adjacent to Bioptimus in AI-driven drug discovery but operates in chemistry-first rather than multimodal-biology-first territory.

TypeDirect peer
Description

Paige builds AI foundation models and clinical decision-support tools for digital pathology, including the FDA-authorized Paige Prostate. It is a direct competitor in pathology foundation models targeting pharma R&D and clinical diagnostics, with comparable multimodal ambitions and a similar customer base in oncology.

TypeDirect peer
Description

DeepHealth applies AI to digital pathology and diagnostic imaging, including its iCAD-acquired and internally developed pathology models. As a SaMD-focused pathology AI company with FDA clearances, it represents Bioptimus's most direct competitor on the clinical commercialization path.

TypeDirect peer
Description

PathAI develops AI-powered pathology tools for both pharma research (biomarker discovery, clinical trial support) and clinical diagnostics. It is a direct peer in computational pathology foundation models, with a strong pharma partnership model and overlapping multimodal ambitions.

7Tempus Labs
TypeBroad incumbent
Description

Tempus is a broad incumbent in AI-driven precision medicine, combining multimodal patient data (pathology, genomics, clinical) with pharma R&D services. While not a foundation-model-first company, it is a key competitor for pharma AI budgets and multimodal data partnerships in oncology.

TypeEmerging player
Description

Recursion combines high-throughput biology with AI foundation models to discover drugs. It is an emerging player in the AI-for-biology category, with comparable multimodal data ambitions (phenoomics, transcriptomics) and a parallel pharma partnership and pipeline model.

TypeRegional player
Description

Artera (the 10x Genomics Atera platform partner) is a digital pathology and multimodal AI company developing prostate cancer and other clinical AI tests. As a 10x Genomics ecosystem partner overlapping with STELA, it is a regional/niche peer in AI-driven pathology biomarker development.

10Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs is Alphabet's AI-for-drug-discovery company, building foundation models of biology (AlphaFold-adjacent). It is a broad incumbent in the same category as Bioptimus's 'world model of biology' ambition, with vastly greater compute resources and a strategic pharma partnership agenda.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bioptimus

AI Foundation Models for Biologybioptimus.com

Bioptimus builds multimodal foundation models for biology (H-Optimus, M-Optimus, STELA) used by 16 of the top 20 pharma companies and 1,000+ academic institutions for drug discovery, biomarker development, and clinical trial enrichment.

What Bioptimus does

Bioptimus is a Paris-based AI startup founded in 2024 that builds multimodal foundation models for biology, targeting pharmaceutical R&D, translational research, and precision medicine. The company's product stack comprises three pillars: H-Optimus, a 1.1 billion-parameter Vision Transformer pathology foundation model (H-Optimus-0 open-source under Apache 2.0; H-Optimus-1 ranked #1 on PathBench and HEST benchmarks across 229 tasks); M-Optimus, the first foundation model that jointly learns from H&E pathology, bulk RNA-seq, spatial transcriptomics, and clinical data to predict the activity of 20,000 genes from routine slides; and STELA, a multi-institutional data engine with 10x Genomics and Broad Clinical Labs targeting up to 100,000 profiled patient specimens across the US, Europe, and Asia. Underlying architecture combines ViT-g/14 image encoders with multimodal pretraining, supporting applications including drug target discovery, biomarker identification, indication expansion, and clinical trial enrichment.

Bioptimus firmographics

Firmographics
Name
Bioptimus
Legal name
Bioptimus
Website
https://bioptimus.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Bioptimus builds multimodal foundation models for biology (H-Optimus, M-Optimus, STELA) used by 16 of the top 20 pharma companies and 1,000+ academic institutions for drug discovery, biomarker development, and clinical trial enrichment.
Ownership category
akta.pro rank

Bioptimus industry classification

Industry
Product category
AI Foundation Models for Biology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (51321)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Foundation models biology
  • Computational pathology AI
  • Multimodal biomedical models
  • Drug discovery AI
  • Spatial transcriptomics

Where Bioptimus is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Bioptimus business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Industry / commercial licensing: Commercial use of H-Optimus-1, H-Optimus-0, M-Optimus, and STELA data atlas requires a separate licensing agreement (industry licenses). Deployed through Amazon SageMaker on AWS Marketplace for enterprise customers. Used by 16 of top 20 pharma companies.
  2. Academic / non-commercial access: Universities and research institutions can request non-commercial research licenses for evaluation and experimental use. H-Optimus-0 is open-source under Apache 2.0; H-Optimus-1 and H0-mini are under CC-BY-NC-ND 4.0 for academic use.
  3. Strategic pharma collaborations & services: Co-development and pilot deployments with pharmaceutical partners (top pharma already onboarded as pioneer partners for M-Optimus), including access to STELA data backbone for joint drug discovery, clinical trial enrichment, and biomarker development programs.

Pricing tiers

ModelBillingPrice
OtherAnnualIndustry license for H-Optimus-1 / M-Optimus (quote-based)
Freemium—Academic non-commercial license

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Bioptimus product offering

Product offering

Core offering

Bioptimus builds and licenses AI foundation models for biology. Its core products are H-Optimus (a state-of-the-art pathology foundation model trained on over 1 million H&E whole-slide images), M-Optimus (a multimodal world model that jointly learns from histology, RNA-seq, spatial transcriptomics, and clinical data), and STELA (a multi-institutional spatial biology atlas initiative). Models are licensed commercially to pharmaceutical and biotechnology customers (with academic/non-commercial access via Hugging Face and AWS Marketplace).

Product overview

Bioptimus offers a unified AI foundation model platform for biology structured around three integrated pillars: (1) H-Optimus, a single-modality pathology foundation model family (H-Optimus-0, H-Optimus-1, H0-mini) that serves as the histopathology backbone for biomarker discovery, patient stratification, and clinical decision support; (2) M-Optimus, the multimodal multi-scale 'world model of biology' that extends H-Optimus by jointly learning from H&E, bulk RNA-seq, spatial transcriptomics, and clinical data to predict gene expression and trial outcomes; and (3) STELA, a collaborative data generation engine that feeds M-Optimus with deeply profiled, clinically linked multimodal patient specimens. Together, these products form a vertically integrated stack in which H-Optimus provides the visual foundation, M-Optimus the reasoning and prediction layer, and STELA the proprietary data backbone, all designed to accelerate drug discovery, de-risk clinical trials, and advance precision medicine.

Differentiator

Problem solved

Functional benefit

Brands

  • H-Optimus: Bioptimus's pathology foundation model family (H-Optimus-0 and H-Optimus-1) for digital histopathology, providing state-of-the-art performance across pathology benchmarks.
  • M-Optimus
  • STELA

Products and services

  • H-Optimus-1 A state-of-the-art 1.1 billion parameter Vision Transformer (ViT-g/14) foundation model for digital pathology, trained on over 1 million H&E whole-slide images from more than 800,000 patients across 4,000+ clinical centers and 50+ organs. Ranked #1 on PathBench across 229 tasks; available on AWS Marketplace and Hugging Face for academic use. Sold via enterprise licensing to pharmaceutical and biotech customers.
  • H-Optimus-0 The original open-source 1.1 billion parameter pathology foundation model, trained on over 500,000 histology slides from 4,000+ clinical practices. Released under Apache 2.0 license, designed for broad academic and research use via Hugging Face.
  • H0-mini A lightweight, computationally efficient pathology model distilled from H-Optimus-0 in collaboration with Owkin, delivering comparable performance to larger foundation models at significantly reduced inference cost. Released under CC-BY-NC-ND 4.0 license for non-commercial academic research on Hugging Face.
  • M-Optimus A multimodal, multi-scale foundation model that combines H&E pathology images, bulk RNA-seq, spatial transcriptomics, and clinical data into a unified embedding space. The first model built to understand biology across every scale, enabling digital twin simulations, drug target prediction, biomarker discovery, and trial design optimization. Request-access only via direct enterprise license.
  • STELA (Spatial Tissue Embedding Learning Atlas) A multi-institutional collaborative data initiative, launched with 10x Genomics and Broad Clinical Labs, designed to generate the world's largest clinically linked multimodal spatial biology atlas profiling up to 100,000 patient tissue specimens across the US, Europe, and Asia. Serves as the proprietary data backbone for M-Optimus.

Quantifiable outcome

  • H-Optimus-1 ranked #1 on PathBench with score 6.06 (vs Virchow 26.34, H-Optimus-0 6.86, UNI 27.10, mSTAR 7.65)
  • +11 more outcomes

Companies that use Bioptimus

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Bioptimus technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability10 records

Feature7 records

Bioptimus partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered flagship and minor.

  • 10x GenomicsflagshipStrategic or Co-development Partner · 25 March 2026Co-launch partner of the STELA multinational spatial biology atlas initiative announced March 25, 2026. Provides the Xenium spatial transcriptomics platform used to profile up to 100,000 patient specimens across US, Europe and Asia. Bioptimus plans to expand from Xenium to Atera in 2027 as part of STELA. Michael Schnall-Levin (CTO and Founding Scientist of 10x Genomics) is a Bioptimus Strategic Advisor.
  • Broad Clinical LabsflagshipStrategic or Co-development Partner · 25 March 2026Co-launch partner of the STELA initiative alongside Bioptimus and 10x Genomics. Contributes high-throughput spatial data generation capabilities to profile up to 100,000 patient tissue specimens across three continents.
  • Massachusetts Institute of Technology (MIT)flagshipStrategic or Co-development Partner · 3 November 2025MIT partners with Bioptimus for the ARPA-H ADAPT Clinical Cancer Prediction Study (case study published November 3, 2025). MIT team led by Professor Regina Barzilay validated H-Optimus-1 as top-performing pathology foundation model for predicting Progression-Free Survival in metastatic breast, lung, and colon cancer. Regina Barzilay (MIT Jameel Clinic) also serves on Bioptimus's Scientific Advisory Board.
  • NVIDIAflagshipTechnology or Integration · 11 June 2025Bioptimus secured access to NVIDIA compute resources (via DGX Cloud Lepton) in June 2025 to accelerate training of its foundation models for biology, in collaboration with Sofinnova Partners.
  • ProsciaminorStrategic or Co-development Partner · 23 October 2024Collaboration announced October 23, 2024 to accelerate AI innovation in scientific research and drug development for improved patient care; jointly hosted a December 2024 webinar on foundation models in pathology AI.
  • OwkinflagshipStrategic or Co-development Partner · 20 February 2024Founding-partner relationship — Bioptimus co-founders include ex-Owkin scientists (Jean-Philippe Vert was Chief R&D Officer; David Cahané was Chief Solutions Officer; Charlie Saillard worked at Owkin for 6 years; Philip Conti-Permanne was Director Corporate Development). Provides multimodal patient data, expertise, and a co-development collaboration for the CytoSyn diffusion model (released Nov 2025 on Hugging Face). Thomas Clozel (Owkin co-founder/CEO) serves as a Strategic Advisor.
  • Amazon Web Services (AWS)flagshipTechnology or Integration · 20 February 2024Provides compute resources and cloud infrastructure. H-Optimus-1 is deployed on AWS Marketplace via Amazon SageMaker (launched May 2025) and M-Optimus / H-Optimus-1 are made available via Amazon SageMaker AI partnership.
  • University of Cambridge / Wellcome Sanger Institute (Sarah Teichmann)minorStrategic or Co-development PartnerSarah Teichmann (Chair in Stem Cell Medicine, University of Cambridge; co-founder EnsoCell Therapeutics) serves as Chair of Bioptimus's Scientific Advisory Board.
  • Columbia University / Chan Zuckerberg Biohub New York (Andrea Califano)minorStrategic or Co-development PartnerAndrea Califano (President of CZI Biohub New York; Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia) sits on Bioptimus's Scientific Advisory Board.
  • Broad Institute / MIT (Caroline Uhler)minorStrategic or Co-development PartnerCaroline Uhler (Director of the Eric & Wendy Schmidt Center at the Broad Institute; Professor of Engineering at MIT) is on Bioptimus's Scientific Advisory Board.
  • Technical University (TU) Dresden (Jakob Kather)minorStrategic or Co-development PartnerJakob Kather (Professor for Clinical AI at TU Dresden; senior physician in medical oncology) is on Bioptimus's Scientific Advisory Board. The Kather Lab at TU Dresden is also a Bioptimus case-study customer using H-Optimus-1 for breast cancer recurrence risk prediction.
  • Parker Institute for Cancer Immunotherapy (PICI) (John Connolly)minorStrategic or Co-development PartnerJohn Connolly (CSO at PICI) sits on Bioptimus's Scientific Advisory Board.
  • Berlin Institute for Medical Systems Biology / Max Delbrück Center (Nikolaus Rajewsky)minorStrategic or Co-development PartnerNikolaus Rajewsky (Scientific and Founding Director, BIMSB at MDC) is on Bioptimus's Scientific Advisory Board.
  • Gustave Roussy / ESMO (Fabrice André)minorStrategic or Co-development PartnerFabrice André (President of ESMO; Director of Research at Gustave Roussy) is on Bioptimus's Scientific Advisory Board.

Scale indicators11 records

Recent moves6 records

Expansion highlights7 records

Bioptimus competitors and assessment

Company assessment

Emerging players

  • Insitro: Insitro uses ML on multimodal biological data (imaging, genomics, functional assays) for drug discovery. It overlaps with Bioptimus on the ML-meets-biology thesis and pharma partnership model, but focuses on owned therapeutic pipelines rather than platform licensing.
  • Exscientia: Exscientia applies AI to small-molecule drug discovery, with a precision medicine focus and pharma partnerships. It is thematically adjacent to Bioptimus in AI-driven drug discovery but operates in chemistry-first rather than multimodal-biology-first territory.
  • Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI foundation models to discover drugs. It is an emerging player in the AI-for-biology category, with comparable multimodal data ambitions (phenoomics, transcriptomics) and a parallel pharma partnership and pipeline model.

Direct peers

  • Owkin: Owkin is Bioptimus's founding partner and most direct competitor, building AI for patient stratification, drug discovery, and pathology. The two share scientific DNA (multiple Bioptimus co-founders came from Owkin) and overlapping multimodal patient data, but Owkin has deeper pharma deployment (e.g., Roche alliance) and a longer commercial track record.
  • Paige.AI: Paige builds AI foundation models and clinical decision-support tools for digital pathology, including the FDA-authorized Paige Prostate. It is a direct competitor in pathology foundation models targeting pharma R&D and clinical diagnostics, with comparable multimodal ambitions and a similar customer base in oncology.
  • DeepHealth (a RadNet company): DeepHealth applies AI to digital pathology and diagnostic imaging, including its iCAD-acquired and internally developed pathology models. As a SaMD-focused pathology AI company with FDA clearances, it represents Bioptimus's most direct competitor on the clinical commercialization path.
  • PathAI: PathAI develops AI-powered pathology tools for both pharma research (biomarker discovery, clinical trial support) and clinical diagnostics. It is a direct peer in computational pathology foundation models, with a strong pharma partnership model and overlapping multimodal ambitions.

Broad incumbents

  • Tempus Labs: Tempus is a broad incumbent in AI-driven precision medicine, combining multimodal patient data (pathology, genomics, clinical) with pharma R&D services. While not a foundation-model-first company, it is a key competitor for pharma AI budgets and multimodal data partnerships in oncology.
  • Isomorphic Labs: Isomorphic Labs is Alphabet's AI-for-drug-discovery company, building foundation models of biology (AlphaFold-adjacent). It is a broad incumbent in the same category as Bioptimus's 'world model of biology' ambition, with vastly greater compute resources and a strategic pharma partnership agenda.

Regional players

  • Artera: Artera (the 10x Genomics Atera platform partner) is a digital pathology and multimodal AI company developing prostate cancer and other clinical AI tests. As a 10x Genomics ecosystem partner overlapping with STELA, it is a regional/niche peer in AI-driven pathology biomarker development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Bioptimus social profiles

Digital presence

Bioptimus compliance and trust

Trust signal

Compliance1 record

Bioptimus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bioptimus leadership team

Management profile

Number of profiles

Profiles10 records

Bioptimus funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bioptimus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioptimus

What does Bioptimus do?

Bioptimus builds and licenses AI foundation models for biology. Its core products are H-Optimus (a state-of-the-art pathology foundation model trained on over 1 million H&E whole-slide images), M-Optimus (a multimodal world model that jointly learns from histology, RNA-seq, spatial transcriptomics, and clinical data), and STELA (a multi-institutional spatial biology atlas initiative). Models are licensed commercially to pharmaceutical and biotechnology customers (with academic/non-commercial access via Hugging Face and AWS Marketplace).

Is Bioptimus a public or private company?

Bioptimus is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bioptimus founded?

Bioptimus was founded in 2024. It employs 11 to 50 people.

Where is Bioptimus based?

Bioptimus is headquartered in Paris, France, in the Europe region.

How does Bioptimus make money?

Three revenue lines are on record. Industry / commercial licensing is the primary driver. The others are academic / non-commercial access and strategic pharma collaborations & services.

Who are Bioptimus's main competitors?

Emerging players on record are Insitro, Exscientia and Recursion Pharmaceuticals. Direct peers are Owkin, Paige.AI, DeepHealth (a RadNet company) and PathAI. Broad incumbents are Tempus Labs and Isomorphic Labs. Artera is listed as a regional player.

Does Bioptimus have an API?

No public API is recorded for Bioptimus.

What industry is Bioptimus in?

Bioptimus's product category is AI Foundation Models for Biology. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmafileBioptimus partners with Cancer Research Horizons to expand AI cancer data setBioptimus partnered with Cancer Research Horizons to access S:CORT, a multimodal colorectal cancer dataset from over 1,750 UK patients. The data will be added to STELA, expanding its clinical coverage, and Bioptimus plans to profile 100,000 specimens globally.pharmaphorumBioptimus, Cancer Research Horizons partner on AI-powered precision medicineBioptimus partnered with Cancer Research Horizons to access the S:CORT colorectal cancer dataset, including over 1,750 patient profiles. The data integrates six modalities and will be added to STELA, a multimodal tissue atlas. Bioptimus has raised $76 million since its February 2024 founding.MobiHealthNewsBioptimus, Cancer Research Horizons partner on AI cancer modelBioptimus has partnered with Cancer Research Horizons to access a dataset of over 1,750 colorectal cancer patients for training its M-Optimus biological foundation model. This agreement provides Bioptimus with randomized treatment arms and multimodal data to enhance the model's ability to predict patient outcomes and therapy responses. The partnership expands Bioptimus' STELA initiative by adding geographic diversity from the United Kingdom.The Next WebFrance's startup funding fell 5% in 2025 as AI concentration grewFrench startups raised €6.7 billion in 2025, down 5% year on year, while US funding grew 38%. AI accounted for 43% of capital, and exits fell 65% to €5.3 billion. Mistral raised 25% of total funding, but French VC funds lost top deals to US and pan-European funds.NewswireThe Quiet Rule Change Tilting $10B Toward Medtech's Most Validated PlatformsThe FDA advanced its real-world evidence framework for medical devices in April 2026, shifting capital toward validated medtech platforms as venture investment in medical devices reached a record $10.4 billion in 2025 with median M&A deal values climbing to $570 million. VentriPoint Diagnostics won a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform VMS+™ 4.0, which converts standard 2D ultrasound scans into detailed 3D heart models comparable to cardiac MRI, and is expanding its global footprint through partnerships in Costa Rica, Canada, and Northern California. Additional sector developments include Senseonics presenting real-world evidence for its year-long Eversense 365 CGM, TransMedics unveiling its CHOPS organ preservation system, WELL Health reporting record 1.27 million Canadian patient visits in Q1 2026, and 10x Genomics announcing a partnership with Bioptimus for a spatial biology data initiative targeting up to 100,000 patient tissue specimens.Stock Titan10x Genomics, Bioptimus Build 100,000-Specimen AtlasThe FDA advanced its real-world evidence framework for medical devices in April 2026, shifting capital toward validated platforms in a $41.64 billion medical imaging market projected to reach $67.87 billion by 2034. 10x Genomics announced a strategic partnership with Bioptimus to anchor the STELA spatial biology initiative, targeting up to 100,000 patient tissue specimens across the United States, Europe, and Asia using 10x Genomics' Xenium platform. Venture investment in medical devices reached a record $10.4 billion in 2025 with median M&A deal values climbing to $570 million, signaling smart money positioning around scalable, multi-geography platforms.SynBioBeta10x Genomics Unveils Atera and Sets a New Bar for Spatial Biology at Scale10x Genomics unveiled Atera, an in situ spatial biology platform for whole-transcriptome spatial analysis, at the AACR Annual Meeting in San Diego on April 18, 2026. The platform can run up to 800 whole-transcriptome samples per year on a single instrument at 1 square centimeter each, with early access partners including the Allen Institute, Brigham and Women's Hospital, and the German Cancer Research Center already generating data that has reshaped assumptions in cancer biology. Commercial adoption is underway, with Macrogen and its US subsidiary Psomagen committing to deploy multiple Atera instruments as the first global CRO on the platform, while Bioptimus plans to expand from Xenium to Atera in 2027 as part of its STELA spatial atlas program.PR NewswireBioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical LabsBioptimus announced the launch of STELA (Spatial Tissue Embedding Learning Atlas), a multinational spatial data generation initiative in partnership with 10x Genomics and Broad Clinical Labs, designed to build the world's largest clinically linked multimodal atlas starting in oncology and immunology. The initiative aims to profile up to 100,000 patient tissue specimens across three continents—representing a ~20-fold increase in scale over existing spatial biology atlases—integrating spatial transcriptomics, histopathology imaging, multi-omics, and longitudinal clinical data. STELA will serve as the data backbone for M-Optimus, Bioptimus's multimodal world model of biology, with the goal of accelerating drug development, enabling more effective immunotherapies, and advancing precision medicine.Stock TitanBioptimus Launches STELA 100,000-Specimen AtlasBioptimus announced the launch of STELA (Spatial Tissue Embedding Learning Atlas), a multinational spatial data generation initiative that aims to profile up to 100,000 patient specimens across three continents, representing approximately a 20-fold increase in scale over existing spatial biology atlases. The initiative is anchored by strategic partnerships with 10x Genomics and Broad Clinical Labs, leveraging the Xenium spatial transcriptomics platform and high-throughput laboratory workflows to generate harmonized multi-omics patient data. STELA will serve as the data backbone for M-Optimus, Bioptimus's multimodal world model of biology, designed to accelerate drug development and advance precision medicine in oncology and immunology.PR NewswireBioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical LabsBioptimus announced the launch of STELA (Spatial Tissue Embedding Learning Atlas), a global initiative to build the world's largest clinically linked multimodal spatial biology atlas by profiling up to 100,000 patient tissue specimens across three continents. The project, anchored by partnerships with 10x Genomics and Broad Clinical Labs, aims to scale the M-Optimus world model of biology by generating harmonized multi-omics data integrating spatial transcriptomics, histopathology imaging, and longitudinal clinical records—a ~20-fold increase over existing spatial biology atlases. This initiative is designed to accelerate drug development and enable more precise diagnostics and immunotherapies by providing standardized, AI-ready data infrastructure for the life sciences industry.